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Background
Human African trypanosomiasis
(HAT), or sleeping sickness, is a vector-
borne disease caused by trypanosomes
(Trypanosoma brucei gambiense and T.b. rhode-
siense) mainly affecting impoverished rural
areas in sub-Saharan Africa, where the
health systems are weak.
Over the last decade, the number of
HAT cases has shown a decreasing trend
as a result of coordinated control efforts
[1]. This makes it possible to envisage the
elimination of the disease, but a new
approach to uphold current results is
needed. Sustainability of the control
efforts will require integration of control
and surveillance activities within a rein-
forced health system [2]. However, the
complexity of the existing diagnostic tools
is not compatible with prevailing condi-
tions at basic health facilities in rural
areas where the disease is endemic, which
hinders the participation of the health
system in the control and surveillance of
the disease [3]. There is an urgent need
for diagnostic tests that are reliable,
cheap, and easy to perform at basic
health services.
In 2006, the Department of Control of
Neglected Tropical Diseases (NTD) of the
World Health Organization (WHO) es-
tablished a collaboration with the Foun-
dation for Innovative New Diagnostics
(FIND, http://www.finddiagnostics.org/)
to develop new diagnostic tools for the
control of HAT that meet the require-
ments of a sustainable elimination ap-
proach. In the framework of this agree-
ment, WHO established a HAT specimen
biobank as a collection of biological
specimens related to HAT, coupled with
clinical and epidemiological information
of the person who donated the specimens.
The specimen biobank is the property of
WHO and its main objective is to provide
clinical reference material to research
institutions to facilitate the development
and evaluation of new tests for the
diagnosis of HAT.
To set up a specimen bank for HAT
first requires the collection of specimens
while strictly following good clinical prac-
tice principles. The specimens have to be
collected in the areas where the disease is
endemic, usually remote areas with limited
health resources and impoverished affect-
ed populations. The specimens collected
have to be well identified and kept in strict
cold chain from the time of collection to
the final storage. To fulfill these conditions
is challenging, but we have proved that it
is not insurmountable.
What Are the Characteristics
and Requirements of the HAT
Biobank?
The WHO HAT biobank includes
specimens from three groups of partici-
pants:
N Cases, defined as individuals where
presence of trypanosomes was con-
firmed.
N Controls, defined as individuals living in
endemic areas with negative serology
(Card Agglutination Test for Trypano-
somiasis, CATT) and parasitology for
HAT, and without evidence of previ-
ous HAT infection.
N Suspects, defined as individuals with
positive serology for HAT but negative
parasitology and no evidence of previ-
ous HAT infection. According to
national protocols, these individuals
usually do not receive treatment but
are followed-up until confirmation or
rejection of the serological suspicion.
They were also asked to participate
during their follow-up (at least one
visit), with specimens taken during
each follow-up visit.
All participants were $12 years old,
and were enrolled only after giving written
informed consent. Informed consent forms
were prepared in different local languages
(Kiswahili, Lingala, Chiluba, Ngambaye,
Kakwa, Kumam, and Lugbara). For
patients unable to give consent due to
HAT-related mental impairment and for
participants under 18 years old, provision
of informed consent was done by the legal
guardian (with an informed assent signed
by the minor).
Specimens collected from each donor
include blood, serum, plasma, saliva, and
urine. In Cases, cerebrospinal fluid (CSF)
was also taken. These specimens were
obtained during routine examination of
the participants. Clinical, epidemiological,
and laboratory data were recorded and
linked to biological specimens.
Specimens are strictly kept below
280uC from collection to delivery to the
final users. The cold chain was based on
immediate storage in liquid nitrogen after
collection, and intermediate storage in the
national centers in liquid nitrogen or in
ultra-low deep freezers while waiting for
shipment on dry ice to the Central
Repository by express courier.
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was approved by the WHO Ethical
Review Committee and the different
national ethical committees in each coun-
try where specimens were collected. The
national Ministries of Health also gave
their approval.
Where Were the Specimens
Collected?
Collection sites were selected accord-
ing to accessibility, security, communica-
tion, number of cases and subspecies of
HAT reported (T.b. rhodesiense and T.b.
gambiense), and available facilities, equip-
ment, and human resources as well as
existing support from recognized national
institutions. The sites selected for the
collection and the national institutions for
intermediate storage were as follows
(Figure 1):
N Democratic Republic of the Congo
(DRC) in partnership with the Sleep-
ing Sickness National Control Pro-
gram (SSNCP) and in collaboration
with the National Institute for Bio-
medical Research (INRB): Two sites in
Kinshasa province (‘‘Ho ˆpital Roi Bau-
douin’’ in Kinshasa and ‘‘Centre de
Diagnostic et de Traitement de la
Maladie du Sommeil’’ [CDT] in Mal-
uku) and four sites in Kasai Orientale
province (the CDT of Dipumba, the
CDT of Katanda, the ‘‘Unite Mobile’’
[UM] of Miabi, and the UM of
Tshilenge).
N United Republic of Tanzania, in
partnership with the National Insti-
tute for Medical Research (NIMR):
Kaliua Health Centre in Urambo
District.
N Guinea, in partnership with the
SSNCP and in collaboration with
the Institut de Recherche pour le
De ´veloppement/Centre International
de Recherche - De ´veloppement sur
l’Elevage en zone subhumide (IRD/
CIRDES): UM working in the HAT
foci of Forecariah, Dubreka, and
Boffa.
N Malawi, in partnership with the
SSNCP and the Centre for Tick and
Tick-borne Diseases (CTTBD): Rum-
phi Hospital in Rumphi district.
N Chad, in partnership with the
SSNCP and the Organisation pour
le Control des Ende ´mies en Afrique
Figure 1. Localities of collection sites of specimens for the HAT specimen biobank (yellow dots). Dark grey indicates HAT-endemic
countries. The bold black line shows the theoretical separation of T.b. gambiense and T.b. rhodesiense areas.
doi:10.1371/journal.pntd.0001571.g001
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the Mandoul focus (Pre ´fecture de
Bodo).
N Uganda, in partnership with the
SSNCP and the University of Maker-
ere: Omugo Health Centre IV in
Maracha-Terego District, and Lwala
Hospital in Kaberamaido District.
Collection of specimens started in 2008
and eventually 949 Cases (113% of total
planned), 759 Controls (91% of total
planned), and 90 Suspects (90% of total
planned) were enrolled (1,798 participants)
(Table 1).
How Were the Specimens
Shipped and Stored?
Following an open tender, the ‘‘Clinical
Investigation and Biomedical Research
Support Unit (ICAReB)’’ of the Institut
Pasteur in Paris was selected as Central
Repository. The Central Repository is in
charge of management of specimens and
associated data, including reception, con-
trol, processing, storage, and subsequent
distribution to end-users, following all
applicable quality standards and regula-
tions. ICAReB obtained all due approvals
from the French Research Ministry and
Ethical Committee Ile-de-France I.
Shipment from intermediate national
storage to the Central Repository was
organized by express courier on dry ice. A
total of 18 shipments were made: seven
from DRC, two from Tanzania, two from
Chad, two from Guinea, three from
Malawi, and two from Uganda.
Specimens from 1,804 participants orig-
inally enrolled arrived at the Central
Repository and were processed and stored
(Table 2). Specimens from 157 partici-
pants (9%) are currently in quarantine due
to lack of key information or inconsisten-
cies in the data forms.
Quality control of the specimens
stored in the Central Repository has
been performed by the WHO collabo-
rating centre for HAT diagnosis based at
the Institute of Tropical Medicine in
Antwerp. A CATT dilution was per-
formed, followed by the immune trypa-
nolysis test [4], when discordance in
CATT results with results from the field
was observed. Specimens from eight
participants were discarded during this
quality control process.
How Are the Specimens
Distributed?
Distribution of the specimens is limited
to qualified investigators involved in the
development and evaluation of new diag-
nostics for HAT that would be appropriate
for use in low-income countries and will
benefit affected populations.
A material request form is available at the
WHO website (http://www.who.int/
trypanosomiasis_african/research/en/) and
should be completed to request specimens.
With this form, the institution provides
specific information on the intended use of
the specimens, and accepts the general
conditions of use. An Exit Committee
examines the request received on pertinence,
relevance, and coherence with the objectives
of the biobank. If the request is accepted, exit
orders are given by WHO to the Central
Repository, which organizes the shipments.
To date, the Exit Committee has received
15 requests for specimens from research
institutions in the United States, Switzer-
Table 1. Number of participants enrolled (by country).
Cases Controls Suspects TOTAL
Planned 840 840 100 1,780
Collected (performance) 949 (113%) 759 (90%) 90 (90%) 1,798 (101%)
Guinea 90 30 42 149
DRC 598 597 48 1,261
Tanzania 18 36 0 55
Malawi 73 70 0 143
C h a d 7 32 60 9 9
Uganda (T.b.g.)5 0 0 0 4 7
Uganda (T.b.r.) 47 0 0 50
T.b.g., T.b. gambiense; T.b.r., T.b. rhodesiense.
doi:10.1371/journal.pntd.0001571.t001
Table 2. Summary of specimens stored in ICAReB, Institut Pasteur, Paris.
Received Controls (C) Cases (P) Suspects (S)
Stage 1 (P1) Stage 2 (P2) Stage X (PX) First (S1) Follow-Up (Sx)
T.b. gambiense 653 182 626 3 90 29
T.b. rhodesiense 106 16 95 27 — —
TOTAL 759 198 721 30 90 29
Total by category 759 949 90 29
TOTAL INDIVIDUALS 1,798 29
P1, case stage 1; P2, case stage2; Px, case stage not determined; C, controls; S1, suspects’ initial visit; Sx, suspects’ follow-up visits.
doi:10.1371/journal.pntd.0001571.t002
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Germany, Korea, Kenya, and France. A
total of 2,890 specimens (1,163 serum, 1,336
plasma, 10 buffy-coat, and 381 CSF) have
been supplied to research institutions based
on the recommendations of the Exit Com-
mittee decisions. The average time from
receiving the request to Exit Committee
decision was 15 days (5–49 days). The
average delivery time after Exit Committee
decision was 48 days (28–120 days).
Request of specimens from the WHO
HAT biobank can be addressed to WHO/
NTD (francoj@who.int, simarrop@who.
int) or by consulting: http://www.who.
int/trypanosomiasis_african/research/en/.
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Learning Points
N To set up a specimen biobank is an expensive and complex task [5–7]. These
problems are increased when the subject of the biobank is a neglected disease
such as HAT, occurring in remote impoverished areas. Despite logistical,
technical and financial difficulties, the HAT biobank has now been set up and is
functional. A large collection of specimens is available for research on new
diagnostic tools. Collection of the specimens has respected ethical principles
and adhered to good clinical and laboratory practice.
N Collaboration of SSNCP and research institutions has been essential to set up
the biobank.
N As collateral benefits, the WHO specimen biobank has also helped to improve
the skills of involved staff, to strengthen the diagnostic capacity in screening
sites, to reinforce current control and surveillance activities (screening, logistics,
and mobile teams), to upgrade equipment of institutions involved in HAT
screening, and to train on ethical aspects of the research.
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